摘要
目的观察替吉奥联合多西他赛和顺铂(DCS方案)一线治疗进展期胃癌的有效性及安全性。方法采用随机、对照、开放性的临床试验设计。入选96例初治的进展期胃癌患者,随机分为2组,治疗组48例采用DCS方案化疗;对照组48例,采用多西他赛、顺铂、亚叶酸钙及氟尿嘧啶方案(DCF方案)化疗;至少化疗3个周期后评价疗效及不良反应。结果治疗组的近期有效率(RR)为83.3%,优于对照组的54.2%,差异有统计学意义(P<0.05);治疗组中位TTP和MST分别为7.5个月和12.1个月,均高于对照组的5.6个月和8.4个月;治疗组的不良反应及严重反应发生率均明显低于对照组(P<0.05)。结论替吉奥联合多西他赛和顺铂化疗方案一线治疗进展期胃癌疗效确切,不良反应较少,患者耐受性良好。
Objective To evaluate the efficacy and safety of the combination of S-1 with Docetaxel and Cisplatin （ DCS therapeutic regimens） as a first line regimen in the treatment of patients with advanced gastric carcinoma. Methods A random- ized, control, open clinical trial was designed ,96 patients with advanced gastric carcinoma were randomly divided into two groups. The experimental group （48 patients） was treated by using the DCS therapeutic schedules; the control group was treated by Doxt- axol, Cisplatin, Calcium Folinate and 5-FU （ DCF therapeutic regimens）. The short-term efficacy and adverse reactions were eval- uated after at least three treatment cycles. Results All the 96 patients were suitable for evaluation. The tumor response rate （RR） of the experimental group was better than that of the control group （83.3 % vs. 54.2%, P 〈 0.05 ）. Besides, the median time to progression （MTI＇P） and median survival time （MST） were 7.5 months and 12.1 months in the experimental group, which were longer than that of the control group （ 5.6 and 8.4 months, respectively）. In addition, compared with the control group, occurrence rate of adverse reactions and serious response of the experimental group were significantly lower （ P 〈 0.05 ）. Conclusion The DCS therapeutic regimen showed definite curative effect in the treatment of patients with advanced gastric car- cinoma with mild adverse effects and better toleration.
出处
《实用癌症杂志》
2013年第2期158-160,182,共4页
The Practical Journal of Cancer
关键词
进展期胃癌
化学治疗
替吉奥
多西他赛
顺铂
Advanced gastric carcinoma
Chemotherapy
S-1
Docetaxel
Cisplatin
